PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment

Neurology

Volumn 68, Issue 19, 2007, Pages 1603-1606

  Kemppainen, N M ^a   Aalto, S ^a,b   Wilson, I A ^f   Nagren K ^a   Helin, S ^a   Bruck A ^a   Oikonen, V ^a   Kailajarvi M ^a   Scheinin, M ^a   Viitanen, M ^c,g   Parkkola, R ^d   Rinne, J O ^a,e  

^a UNIVERSITY OF TURKU   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

^c TURKU CITY HOSPITAL   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e Turku Imanet Ltd   (Finland)

^f GE HEALTHCARE   (United Kingdom)

^g KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; APOLIPOPROTEIN E4; LIGAND; N METHYL 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE C 11; TRACER; UNCLASSIFIED DRUG;

AGED; ALLELE; ALZHEIMER DISEASE; ANAMNESIS; ARTICLE; AUTOMATION; BRAIN CORTEX; BRAIN REGION; CAUDATE NUCLEUS; CEREBELLUM; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; FRONTAL CORTEX; HUMAN; MALE; PARAMETERS OF MEASUREMENT AND ANALYSIS; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; STATISTICAL SIGNIFICANCE; TEMPORAL CORTEX;

AGED; ALZHEIMER DISEASE; AMNESIA; AMYLOID BETA-PROTEIN; BENZOTHIAZOLES; BRAIN; BRAIN MAPPING; COGNITION DISORDERS; FEMALE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; SENILE PLAQUES;

EID: 34248231779     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000260969.94695.56     Document Type: Article

References (18)

1. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-1342.
2. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
3. Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005;64:1294-1297.
4. Jack CR Jr, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005;65:1227-1231.
5. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-319.
6. Kemppainen N, Aalto S, Wilson IA, et al. Voxel based analysis of amyloid ligand [11C]PIB uptake in Alzheimer's disease Neurology 2006;67:1575-1580.
7. Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967-972.
8. Meyer JH, Gunn RN, Myers R, et al. Assessment of spatial normalization of PET ligand images using ligand-specific templates. Neuroimage 1999;9:545-553.
9. Brück A, Aalto S, Nurmi E, et al. Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol Aging 2005;26:891-898.
10. Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 2006;63:38-46.
11. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-259.
12. Thal DR, Rub U, Orantes M, et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-1800.
13. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-7717.
14. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452.
15. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003;289:2094-2103.
16. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512-519.
17. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995;333:1242-1247.
18. Pennanen C, Kivipelto M, Tuomainen S, et al. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging 2004;25:303-310.